JCB, Volume 12, Number 1, 2005 Editorial Vol.12 No. 1 (2005) Editorial: De-risking novel therapeutic development – time to stop blaming the molecule? Simon Shohet   Commentary Vol.12 No. 1 (2005) The European biotech sector: Could it achieve more? Sam Fazeli There is a general feeling among investors and other observers that the European biotech sector has not delivered and fund managers complain that there have been very f Article Vol.12 No. 1 (2005) What to do when your technology is good but a licence is terminated Manon Cox One of the biggest challenges in the biotech industry is to secure sufficient funding to support product or technology development. Partnering with companies that have Article Vol.12 No. 1 (2005) Future employment in biotechnology in Germany Klaus Menrad This paper quantitatively analyses the employment effects of biotechnology in Germany. In 2000, a total of 614,000 employees were influenced by this technology of which Article Vol.12 No. 1 (2005) Human Tissue Act 2004: The age of consent arrives in the UK Gillian Johnson The organ collection scandals of Alder Hey and Bristol Royal Infirmary in the UK were the driving force for a comprehensive overhaul of the legislation and regulation o Article Vol.12 No. 1 (2005) Rethinking innovation in pharmaceutical R&D Ann Baker The pharmaceutical industry is facing a challenge to be productive. One of the solutions to this problem is for the industry to better harness innovation to deliver mor Article Vol.12 No. 1 (2005) Managing innovation in the pharmaceutical industry Esther F Schmid Innovation is the lifeblood of the pharmaceutical industry, and has been a major driver of industry growth, as well as providing major advances for patients and society Article Vol.12 No. 1 (2005) Taking stock in biotechnology futures John L Jacobs Investors now have a new tool to help them manage the risk associated with biotechnology investment. Individual and professional investors can more confidently invest i Article Vol.12 No. 1 (2005) Biotechnology in India: Emerging opportunities Himanshu Parmar The global biotechnology and pharmaceutical industry is beleaguered with several challenges such as high R&D costs, increasing regulatory restraints and stagnant pr Article Vol.12 No. 1 (2005) Marketspace: Leading therapeutic recombinant protein sales forecast and analysis to 2010 Mark J Belsey As part of Datamonitor's biotechnology strategic market analysis, the authors have performed an analysis of the top 20 therapeutic recombinant proteins (defined by 2010 Legal and Regulatory Updates Vol.12 No. 1 (2005) Legal and regulatory update John Wilkinson The European Commission has launched a public consultation on its proposed amendments to the Medical Devices Directive (MDD) (Dir 93/42/EEC). The aim of the European Co